|
US5217879A
(en)
|
1989-01-12 |
1993-06-08 |
Washington University |
Infectious Sindbis virus vectors
|
|
EP0819250B1
(en)
|
1995-04-06 |
2006-09-20 |
Miltenyi Biotec Inc. |
Multiparameter cell separation using releasable colloidal magnetic particles
|
|
US6458560B1
(en)
|
1996-04-05 |
2002-10-01 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
AU757549B2
(en)
|
1998-03-27 |
2003-02-27 |
Cytos Biotechnology Ag |
Inducible alphaviral gene expression system
|
|
AU4932199A
(en)
|
1998-07-31 |
2000-02-21 |
Haruo Sugiyama |
Cancer antigens based on tumor suppressor gene wt1 product
|
|
US8647864B2
(en)
|
1999-04-14 |
2014-02-11 |
Novartis Ag |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
|
CA2373300C
(en)
|
1999-04-14 |
2012-02-21 |
Chiron Corporation |
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
|
|
WO2000070070A1
(en)
|
1999-05-18 |
2000-11-23 |
Dnavec Research Inc. |
Paramyxoviridae virus vector defective in envelope gene
|
|
US20030232324A1
(en)
|
2001-05-31 |
2003-12-18 |
Chiron Corporation |
Chimeric alphavirus replicon particles
|
|
CA2448066A1
(en)
|
2001-05-31 |
2002-12-12 |
Chiron Corporation |
Chimeric alphavirus replicon particles
|
|
WO2003023026A1
(en)
|
2001-09-06 |
2003-03-20 |
Alphavax, Inc. |
Alphavirus replicon vector systems
|
|
BR0313113A
(pt)
|
2002-08-13 |
2005-06-28 |
Akzo Nobel Nv |
Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina
|
|
US7820181B2
(en)
*
|
2002-09-18 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
|
|
WO2004055161A2
(en)
|
2002-12-12 |
2004-07-01 |
The Board Of Regents Of The University Of Texas System |
Large scale production of packaged alphavirus replicons
|
|
AU2003297041B2
(en)
|
2002-12-13 |
2009-02-26 |
Alphavax, Inc. |
Alphavirus particles and methods for preparation
|
|
EP1608762B1
(en)
|
2003-03-20 |
2014-01-08 |
Alphavax, Inc. |
Improved alphavirus replicons and helper constructs
|
|
US20050282279A1
(en)
*
|
2003-05-29 |
2005-12-22 |
Hwu Paul L |
Expression vector encoding coronavirus-like particle
|
|
WO2004108937A1
(en)
*
|
2003-06-04 |
2004-12-16 |
Bioleaders Corporation |
Cell surface expression vector of sars virus antigen and microorganisms transformed thereby
|
|
US7541038B2
(en)
|
2003-06-05 |
2009-06-02 |
Wyeth Holdings Corporation |
Fusogenic, self-propagating blebs as immunogenic compositions
|
|
PT1751289E
(pt)
|
2004-05-18 |
2009-03-31 |
Alphavax Inc |
Vectores de alfavirais derivados da tc-83, partículas e métodos
|
|
US7332322B2
(en)
|
2004-09-14 |
2008-02-19 |
Ilya Frolov |
Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
|
|
US7998733B2
(en)
|
2004-10-05 |
2011-08-16 |
Merial Limited |
Chimeric vectors
|
|
JP4478788B2
(ja)
|
2005-05-27 |
2010-06-09 |
独立行政法人産業技術総合研究所 |
センダイウイルス温度感受性株由来のウイルスベクター
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
EP2565201B1
(en)
|
2005-10-17 |
2014-11-26 |
Sloan-Kettering Institute For Cancer Research |
WT1 HLA class II-binding peptides and compositions and methods comprising same
|
|
WO2007098267A2
(en)
|
2006-02-27 |
2007-08-30 |
The Board Of Regents Of The University Of Texas System |
Pseudoinfectious flavivirus and uses thereof
|
|
US20090047255A1
(en)
|
2006-11-03 |
2009-02-19 |
Alphavax, Inc. |
Alphavirus and Alphavirus Replicon Particle Formulations and Methods
|
|
MX352947B
(es)
|
2007-02-27 |
2017-12-14 |
Int Inst Cancer Immunology Inc |
Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo.
|
|
US8748591B2
(en)
|
2007-04-17 |
2014-06-10 |
The Board Of Regents Of The University Of Texas System |
Chimeric sindbis-western equine encephalitis virus and uses thereof
|
|
EP2143794A1
(en)
*
|
2007-04-27 |
2010-01-13 |
Kyushu University, National University Corporation |
Viral vector for gene therapy
|
|
WO2009079185A2
(en)
*
|
2007-11-26 |
2009-06-25 |
Novartis Vaccines And Diagnostics, Inc. |
Methods of generating alphavirus particles
|
|
WO2009072610A1
(ja)
|
2007-12-05 |
2009-06-11 |
International Institute Of Cancer Immunology, Inc. |
癌ワクチン組成物
|
|
JP5758632B2
(ja)
|
2008-01-24 |
2015-08-05 |
ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System |
蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用
|
|
EP2130912A1
(en)
|
2008-06-04 |
2009-12-09 |
Institut für Viruskrankeiten und Immunprophylaxe |
Pestivirus replicons providing an RNA-based viral vector system
|
|
WO2010008054A1
(ja)
|
2008-07-16 |
2010-01-21 |
ディナベック株式会社 |
染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法
|
|
EP2451475A2
(en)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Self replicating rna molecules and uses thereof
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
KR102266691B1
(ko)
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
US9402890B2
(en)
|
2011-02-01 |
2016-08-02 |
Uab Research Foundation |
Methods and compositions for pseudoinfectious alphaviruses
|
|
US9636410B2
(en)
*
|
2011-07-06 |
2017-05-02 |
Glaxosmithkline Biologicals Sa |
Cationic oil-in-water emulsions
|
|
EP3520810A3
(en)
|
2012-01-13 |
2019-11-06 |
Memorial Sloan-Kettering Cancer Center |
Immunogenic wt1 peptides and use thereof
|
|
AU2013266496B2
(en)
|
2012-05-21 |
2018-08-09 |
The Regents Of The University Of California |
Generation of human iPS cells by a synthetic self- replicative RNA
|
|
US8961995B2
(en)
|
2012-09-20 |
2015-02-24 |
Uab Research Foundation |
Methods and compositions for alphavirus replicons
|
|
WO2014089513A1
(en)
|
2012-12-06 |
2014-06-12 |
Synthetic Genomics, Inc. |
Autonomous replication sequences and episomal dna molecules
|
|
LT2945647T
(lt)
|
2013-01-15 |
2021-02-25 |
Memorial Sloan Kettering Cancer Center |
Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
WO2014134539A1
(en)
|
2013-02-28 |
2014-09-04 |
President And Fellows Of Harvard College |
Methods and compositions for mobilizing stem cells
|
|
EP2968392B1
(en)
|
2013-03-15 |
2020-08-05 |
Elixirgen Therapeutics, Inc. |
Methods of using zscan4 for rejuvenating human cells
|
|
US12374421B2
(en)
|
2013-06-10 |
2025-07-29 |
Iogenetics, Llc |
Bioinformatic processes for determination of peptide binding
|
|
WO2015046229A1
(ja)
|
2013-09-24 |
2015-04-02 |
ディナベック株式会社 |
多能性幹細胞の誘導効率を改善する方法
|
|
AU2014369774B2
(en)
*
|
2013-12-20 |
2020-11-26 |
Boehringer Ingelheim Vetmedica Gmbh |
PRRS virus variant, European PRRS virus cDNA clone, and uses thereof
|
|
US10174317B2
(en)
|
2014-02-13 |
2019-01-08 |
Synthetic Genomics, Inc. |
Recombinant RNA particles and methods of use
|
|
US10266834B2
(en)
|
2014-02-13 |
2019-04-23 |
Synthetic Genomics, Inc. |
Recombinant RNA particles and methods of producing proteins
|
|
JP6769880B2
(ja)
|
2015-02-02 |
2020-10-14 |
株式会社Idファーマ |
改良されたマイナス鎖rnaウイルスベクター
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
JP6913032B2
(ja)
*
|
2015-05-20 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
共通ネオ抗原
|
|
US10695385B2
(en)
|
2015-06-25 |
2020-06-30 |
National University Corporation Kobe University |
Oral cancer vaccine
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
WO2017026776A1
(en)
|
2015-08-10 |
2017-02-16 |
Cellivery Therapeutics, Inc. |
Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof
|
|
US10166281B2
(en)
|
2015-09-04 |
2019-01-01 |
Vlp Therapeutics, Llc |
Method and composition for modulating immune response
|
|
DK3375874T3
(da)
|
2015-11-13 |
2022-05-09 |
Id Pharma Co Ltd |
Forbedret paramyxovirus-vektor
|
|
SG11201804197RA
(en)
|
2015-11-18 |
2018-06-28 |
Orbis Health Solutions Llc |
T7 alpha viral vector system
|
|
HUE059694T2
(hu)
|
2015-11-20 |
2022-12-28 |
Memorial Sloan Kettering Cancer Center |
Készítmény rák kezelésére
|
|
GB201603374D0
(en)
|
2016-02-26 |
2016-04-13 |
Ucl Business Plc |
Packaging cell
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
JP7250520B2
(ja)
|
2016-04-13 |
2023-04-03 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
組換えアルテリウイルスレプリコン系およびその使用
|
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
US20190216956A1
(en)
*
|
2016-07-27 |
2019-07-18 |
The Trustees Of Columbia University In The City Of New York |
Compositions for radiotherapy and uses thereof
|
|
ES2993107T3
(en)
|
2016-10-17 |
2024-12-23 |
Janssen Pharmaceuticals Inc |
Recombinant virus replicon systems and uses thereof
|
|
US10487105B2
(en)
|
2016-10-19 |
2019-11-26 |
Arcturus Therapeutics, Inc. |
Trinucleotide MRNA cap analogs
|
|
WO2018081318A1
(en)
*
|
2016-10-25 |
2018-05-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
|
JP7788787B2
(ja)
|
2016-12-05 |
2025-12-19 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
遺伝子発現増強のための組成物および方法
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
WO2018161092A1
(en)
|
2017-03-03 |
2018-09-07 |
New York University |
Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
|
|
WO2018170347A1
(en)
*
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
US11015204B2
(en)
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
|
KR102823029B1
(ko)
|
2017-12-20 |
2025-06-20 |
브이엘피 테라퓨틱스 인코포레이티드 |
알파바이러스 레플리콘 입자
|
|
KR20200111729A
(ko)
|
2018-01-19 |
2020-09-29 |
얀센 파마슈티칼즈, 인코포레이티드 |
재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
|
|
CN118436618A
(zh)
|
2018-05-30 |
2024-08-06 |
川斯勒佰尔公司 |
信使rna疫苗及其用途
|
|
WO2021119545A1
(en)
|
2019-12-11 |
2021-06-17 |
Gritstone Bio, Inc. |
Durable vaccination
|
|
KR102764120B1
(ko)
|
2019-12-31 |
2025-02-06 |
엘릭서젠 쎄라퓨틱스, 인크. |
핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
|
|
MX2022007910A
(es)
|
2019-12-31 |
2022-08-25 |
Elixirgen Therapeutics Inc |
Distribucion transitoria basada en temperatura de ácidos nucleicos y proteínas de zscan4 a células y tejidos.
|
|
US20230310581A1
(en)
|
2020-04-27 |
2023-10-05 |
Ohio State Innovation Foundation |
A live attenuated measles virus vectored vaccine for sars-cov-2
|
|
EP4168042A1
(en)
|
2020-06-19 |
2023-04-26 |
Ziphius Vaccines |
Self-amplifying sars-cov-2 rna vaccine
|